13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • HPV Oropharynx

    Acronym: 

    TROG 12.01

    ACTRN/NCT /ethics: 

    ACTRN12613000279729 Ethics: 408.14

    Scientific title: 

    A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma

    Summary of trial and patient characteristics

    Cancer Type Head and Neck
    Trial Type Treatment
    Phase Clinical Trials - Phase Tumour Stream Head and Neck
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2013-06-17
    Molecular Target Anticipated End Date 2021-05-31
    Cancer Type Head and Neck
    Trial Type Treatment
    Phase Clinical Trials - Phase
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Head and Neck
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2013-06-17
    Anticipated End Date 2021-05-31

    Trial Summary

    This study aims to compare radiation treatment combined with either cetuximab or cisplatin in patients with locoregionally advanced HPV positive oropharyngeal squamous cell carcinoma (OPSCC) (located at the base of tongue or tonsil)

    Lay Summary

    A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma

    Sponsor / Cooperative group

    Trans-Tasman Radiation Oncology Group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Shawgi Sukumaran Recruitment on Hold